|
|
|
| home > white papers > Analysis of Biopharmaceuticals to Conform to ICHQ6B - RSSL |
|
|
 WHITE PAPERS |
|
RSSL
|
+44 (0)118 918 4024
|
|
http://www.rssl.com
|
|
University of Reading, Whiteknights Rd, Reading, West Berkshire RG6 6LA
|
|
|
Analysis of Biopharmaceuticals to Conform to ICHQ6B
|
|
Worldwide, the pharmaceuticals market is anticipated to grow from more
than USD 782 billion in 2011 to approach a value of just over USD 971
billion by the end of 2016, registering a CAGR of over 24%. In 2010 the
average medicines expenditure per person within the UK was £271, and
this is expected to increase with the ageing population. A significant
and increasing proportion of these sales are protein-based
biotherapeutics or biomolecules. Currently, these account for 19% of the
total market, and are growing at twice the rate of traditional small
molecule pharmaceuticals. It is predicted that close to 50% of the top
100 pharmaceutical products will be biomolecules by 2016. By far the
largest segment of the biopharmaceutical market is the monoclonal
antibody (MAb) with an estimated share of 25.6%, which corresponds to
USD 51.1 billion.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Three-tiered, mobile-app driven program tracks individuals’ physical and psychological symptoms from COVID-19
RALEIGH, N.C., March 20, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences announced today the commercial availability of the COVID-19 Monitoring Program, a mobile app-driven, tiered initiative that allows employers, payers, providers and health systems to track the health and wellbeing of individuals who may be asymptomatic, exposed or diagnosed with COVID-19 during the pandemic.
More info >> |
|
 |
White Papers |
 |
|
The Process of Informed Consent (written by ACRP)
CenterWatch
Every investigator and clinical research coordinator (CRC) should recognize the importance of obtaining valid and appropriate informed consent as an important protection of the rights and welfare of human subjects. The purpose of this ACRP guidance document is not to provide a literature review or summarize the recommendations of various working groups. Instead, the Association decided it would be helpful to provide short and focused guidance which describes how to best structure the informed consent process in accordance with best practices.
More info >> |
|
 |
Industry Events |
 |
SMi Presents the 4th Annual: Highly Potent Active Pharmaceutical Ingredients (HPAPI)
11-13 May 2020, Copthorne Tara Hotel, London, UK
Announcement: Due to ongoing concerns over COVID-19 this conference is now available with remote access only
More info >> |
|
|
|
